GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-02-14| Partnerships

FDA Clears Exelixis, Sairopa’s SIRPα Antibody For Solid Tumor Trial

by Joy Lin
Share To

Exelixis Inc. and Sairopa B.V. have received the go-ahead from the U.S. FDA to begin a clinical trial assessing ADU-1805, a SIRPα monoclonal antibody in adults with advanced solid tumors. 

The two companies designed ADU-1805 to be active against all human alleles of SIRPα, which gives the drug the potential to treat a broader patient population than other SIRPα therapies. 

“The clearance of this Investigational New Drug Application for ADU-1805 is an exciting milestone for our expanding biologics pipeline, marking the first of many anticipated advancements we expect this year,” said Vicki L. Goodman, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 

“Based on its best-in-class potential and broad applicability, we look forward to learning more about ADU-1805 from the upcoming phase 1 trial across multiple tumor types, as we continue toward our goal of finding innovative solutions for patients with advanced cancers.”

Related Article: JPM23: Partnerships Take off From JP Morgan Healthcare Conference 2023 Day One

Blocking the “Don’t-Eat-Me” Interaction between SIRPα and CD47

SIRPα is expressed by immune cells such as macrophages and dendritic cells. When it binds to CD47, also known as the “don’t-eat-me” signal, SIRPα triggers a signaling cascade that inhibits phagocytosis. Cancer cells often express CD47 as an immune escape mechanism.

Due to their therapeutic potential, the SIRPα/CD47 axis has been a target of major acquisitions and collaborations, such as Pfizer’s $2.3 billion acquisition of Trillium Therapeutics for a pair of SIRPα-Fc fusion proteins. Meanwhile, GS-0189, an anti-CD47 antibody and fruit of Gilead’s $4.7 billion buyout of Forty Seven, is undergoing a clinical trial in myelodysplastic syndrome. 

By blocking SIRPα, ADU-1805 could potentially improve the immune system’s ability to attack tumors. The antibody has also been optimized to bind preferentially to SIRPα compared to other members of the SIRP family. 

Under a collaboration established last November, Exelixis holds the option to license ADU-1805 and other anti-SIRPα antibodies upon review of data from Phase 1 clinical studies of ADU-1805, which would be conducted by Sairopa. The recent clearance from the FDA triggers a $35 million milestone payment to Sairopa, which would be paid in the first quarter of 2023. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
M&A
Pfizer Acquires Seagen for $43 Billion to Capture Leading Position in Oncology
2023-03-14
Jounce Sells Anti-CCR8 Antibody to Gilead, Forgoing $645 Million In Milestones
2022-12-28
Exelixis, Cybrexa Pen $700 Million Deal Over Peptide-Drug Conjugate
2022-11-02
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top